


AMENDMENT TO THE CLAIMS

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

In the Claims:

1. (Currently amended) A drug delivery ophthalmic lens comprising a cationic group-containing drug in the inside of a copolymer, wherein the copolymer consists of:



- (a) a hydrophilic monomer having a hydroxyl group in its molecule;
- (b) at least one phosphate group-containing methacrylate represented by the following structural formula (I),



(I);

- (c) a monomer having a nitrogen atom in its side chain; and
- (d) a monomer copolymerizable with (a), (b) and (c),

wherein a mixture of the following structural formulae (II) and (III) is used as the phosphate group-containing methacrylates:



wherein the monomer having a nitrogen atom in its side chain is (meth)acrylamide.

2. (Cancelled)

3. (Original) The drug delivery ophthalmic lens according to claim 1, wherein the content of the monomer having a nitrogen atom in its side chain is 0.05 to 40 wt %.

4. (Cancelled)

5. (Original) The drug delivery ophthalmic lens according to claim 1, wherein the cationic group-containing drug is an organic compound having at least one quaternary ammonium base or primary to tertiary amine base in its molecule.

6. (Currently amended) A drug delivery ophthalmic lens comprising an anionic group-containing drug in the inside of a copolymer consisting of a hydrophilic monomer, cationic and anionic monomers, and a monomer copolymerizable with these components, wherein the copolymer contains the anionic monomer in a ratio of 30 to 90 mol % to the cationic monomer, wherein the anionic group-containing drug is an organic compound having at least one member selected from a carboxyl group, a sulfo group and a phosphate group in its molecule.

7-10. (Cancelled)

11. (Previously presented) The drug delivery ophthalmic lens of claim 6, wherein the copolymer contains the anionic monomer in a ratio of 40 to 80 mol % to the cationic monomer.

12. (Previously presented) The drug delivery ophthalmic lens of claim 11, wherein the anionic group-containing drug is water-soluble azulene.

13. (Cancelled)

14. (Previously Presented) The drug delivery ophthalmic lens according to claim 3, wherein the monomer having a nitrogen atom in its side chain is (meth)acrylamide.

15. (Previously presented) The drug delivery ophthalmic lens according to claim 14, wherein the cationic group-containing drug is an organic compound having at least one quaternary ammonium base or primary to tertiary amine base in its molecule.

16. (Previously Presented) The drug delivery ophthalmic lens according to claim 3, wherein the total amount of the monomers of structural formulae (II) and (III) is 0.5 to 20 wt.% based on the amount of monomers in total, and the amount of the compound of the structural formula (II) is 75 to 85 wt. % based on the total amount of the monomers of the structural formulae (II) and (III).

17. (Cancelled)

18. (Previously Presented) The drug delivery ophthalmic lens according to claim 16, wherein the cationic group-containing drug is naphazoline nitrate.